Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Tumor markers Stories

2014-01-22 12:11:01

Genetic counseling delivered over the telephone is as effective as face-to-face counseling, finds the largest randomized study to date comparing the two methods. The multi-center study, led by researchers at Georgetown Lombardi Comprehensive Cancer Center, was reported today in the Journal of Clinical Oncology. The landscape of genetic testing has broadened to include a range of diseases, and demand for testing and counseling has greatly increased because of direct-to-consumer marketing,...

2014-01-16 16:24:13

Providing Corporate Update on Key Projects QUEBEC CITY, Jan. 16, 2014 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation") today reported financial and operational results for the fourth quarter 2013 and fiscal year ended October 31, 2013. The Corporation announced a net loss of $1,334,099 or $0.03 per share for the fourth quarter ended October 31, 2013, compared to $1,978,355 or $0.05 per share for the same period in 2012 and a net loss of $3,566,942 or...

2014-01-11 23:01:48

The US Supreme court ruled recently that the test patent is no longer valid causing pricing for Genetic testing to plummet. Thousand Oaks, CA (PRWEB) January 11, 2014 BRCA gene is currently the most well known breast cancer (and ovarian cancer) gene. Women with a BRCA1 and/or BRCA2 gene mutation are up to eight times more likely to develop breast malignancy than women without. In other words, the lifetime risk for getting breast cancer is up to 85%. If and when cancer happens, it tends...

2013-11-27 15:48:08

Women who are members of families with BRCA2 mutations but who test negative for the family-specific BRCA2 mutations are still at greater risk for developing breast cancer compared with women in the general population, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Women with certain mutations in their BRCA1 or BRCA2 genes are at increased risk for breast cancer. However, if a woman who comes...

2013-10-28 12:26:27

NEW BRUNSWICK, N.J., Oct. 28, 2013 /PRNewswire-USNewswire/ -- Researchers from GeneAssess, Inc., a Foundation Venture Capital Group portfolio company, announce the publication of the genetic studies that led to the identification of the FRY gene as a breast cancer susceptibility suppressor gene. "We see great promise in Dr. Zarbl's discovery of the FRY gene and how it might be used to affect the diagnosis and treatment of aggressive breast cancers," noted James M. Golubieski, president of...

2013-10-17 16:37:52

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers. The study, carried out by researchers at the UCL Department of Women's Cancer, found that abnormal levels of female hormones in the bloodstream could be the answer. The findings have already led to more research into...

2013-10-15 08:33:34

Also Releases Results from National Harris Survey Revealing Widespread Confusion about BRCA Testing MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of BRCAvantage(TM), a suite of four new lab-developed genetic tests (LDT) that identify mutations in BRCA1 and BRCA2 genes, which are associated with increased risk of inherited breast and ovarian cancers. Serving...

2013-10-15 08:29:13

Seventy-two Percent (72 percent) of Adult Women in the U.S. Have Never Heard of BRCA Testing, yet 58 Percent Would Want to Know if They Carried High-Risk Gene Mutations MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- According to the results of a recent Quest Diagnostics (NYSE: DGX) survey, seventy-two percent (72 percent) of American women age 18 and older have never heard of the BRCA test, a genetic test that can identify mutations in BRCA1 and BRCA2 genes associated with increased risk of...

2013-10-14 09:20:41

A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumor cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague. "The research of the circulating tumor cells (CTC) is of utmost importance, because nowadays there is no reliable marker of both cancer-specific or...

2013-10-08 13:53:37

Technology as sensitive as standard methodology but more efficient, say researchers in the Journal of Molecular Diagnostics The recognition of a causal link between mutations in BRCA1 and BRCA2 genes and increased risk of developing breast and ovarian cancer has intensified the demand for genetic testing. Identifying mutations in these large genes by conventional methods can be time consuming and costly. A report in the November issue of the Journal of Molecular Diagnostics describes a new...